| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
69,710,000 |
| Market
Cap: |
19.45(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2465 - $0.6247 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Synlogic is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of synthetic biotic medicines. Co.'s pipeline includes SYNB1618 and SYNB1934, which are orally administered, non-systemically absorbed drug candidates being studied as potential treatments for phenylketonuria; SYNB1353, which is an orally administered, non-systemically absorbed drug candidate designed to consume methionine in the gastrointestinal tract thereby lowering homocysteine levels in patients with homocystinuria; and SYNB8802, which is an orally administered, non-systemically absorbed drug candidate being developed for the treatment of enteric hyperoxaluria.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
9,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$10,640 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
560 |
560 |
560 |
28,593 |
| Total Sell Value |
$969 |
$969 |
$969 |
$17,110 |
| Total People Sold |
2 |
2 |
2 |
4 |
| Total Sell Transactions |
2 |
2 |
2 |
5 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dooley Mary Beth |
Head of Finance |
• – – |
2024-04-02 |
4 |
S |
$1.73 |
$325 |
D/D |
(188) |
15,231 |
|
- |
|
| Awad Antoine |
Chief Operating Officer |
• – – |
2024-04-02 |
4 |
S |
$1.73 |
$644 |
D/D |
(372) |
33,859 |
|
- |
|
| Dooley Mary Beth |
Head of Finance |
• – – |
2024-03-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,419 |
|
- |
|
| Ma-Weaver Jacob |
|
– – – |
2024-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,312,219 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2023-10-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,922,773 |
|
- |
|
| Brennan Aoife |
See Remarks |
• • – |
2023-04-03 |
4 |
AS |
$0.58 |
$10,964 |
D/D |
(19,042) |
256,301 |
|
-12% |
|
| Jensen Michael Vangsted |
Chief Financial Officer |
• – – |
2023-04-03 |
4 |
S |
$0.58 |
$1,470 |
D/D |
(2,553) |
46,947 |
|
12% |
|
| Awad Antoine |
Chief Operating Officer |
• – – |
2023-04-03 |
4 |
S |
$0.58 |
$3,707 |
D/D |
(6,438) |
74,732 |
|
12% |
|
| Jensen Michael Vangsted |
Chief Financial Officer |
• – – |
2022-05-24 |
4 |
B |
$1.12 |
$10,640 |
D/D |
9,500 |
39,500 |
2.74 |
-11% |
|
| Awad Antoine |
Chief Operating Officer |
• – – |
2022-04-04 |
4 |
AS |
$2.45 |
$6,482 |
D/D |
(2,650) |
81,170 |
|
-52% |
|
| Brennan Aoife |
See Remarks |
• • – |
2022-04-04 |
4 |
AS |
$2.45 |
$21,754 |
D/D |
(8,894) |
275,343 |
|
-52% |
|
| Jensen Michael Vangsted |
Chief Financial Officer |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Awad Antoine |
Chief Operating Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
40,820 |
83,820 |
|
- |
|
| Brennan Aoife |
See Remarks |
• • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
106,920 |
284,237 |
|
- |
|
| Khuong Chau Quang |
Director |
– • – |
2021-04-20 |
4 |
A |
$3.00 |
$4,999,998 |
I/I |
1,666,666 |
3,696,662 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • – |
2021-04-20 |
4 |
A |
$3.00 |
$4,999,998 |
I/I |
1,666,666 |
3,696,662 |
|
- |
|
| Riese Richard J. |
Chief Medical Officer |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
39,000 |
|
- |
|
| Brennan Aoife |
See Remarks |
• • – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
71,250 |
177,317 |
|
- |
|
| Awad Antoine |
Chief Operating Officer |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
43,000 |
|
- |
|
| Awad Antoine |
Chief Operating OfficerOfficer |
• – – |
2020-07-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,500 |
|
0% |
|
| Riese Richard J. |
Chief Medical Officer |
• – – |
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,500 |
21,500 |
|
- |
|
| Brennan Aoife |
See Remarks |
• • – |
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
46,300 |
106,067 |
|
- |
|
| Shea Richard P |
Director |
– • – |
2019-12-13 |
4 |
B |
$2.74 |
$20,550 |
D/D |
7,500 |
7,500 |
2.39 |
- |
|
| Ginkgo Bioworks, Inc. |
10% Owner |
– – • |
2019-06-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,340,771 |
|
- |
|
| Miller Paul Francis |
Chief Scientific Officer |
• – – |
2019-02-13 |
4 |
AS |
$9.75 |
$57,028 |
D/D |
(5,849) |
48,135 |
|
- |
|
128 Records found
|
|
Page 1 of 6 |
|
|
